Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry2026 · 2 citations
2. 2Real‐world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood2024 · 15 citations
3. 3Successful Treatment of Refractory Erythroderma With Abrocitinib：A Case Report2026
4. 4Efficacy and Predictors of Low-Dose Abrocitinib in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: A Prospective Study.2025
5. 5Abrocitinib: 1‐Year Real‐Life Experience From the French OMCCI Registry2026